MSC-2530818 free base · Synonyms: MSC 2530818 · MSC2530818

MSC2530818 is a potent, selective and orally available CDK8 inhibitor.

For research use only. Not for human or veterinary use.

Target CDK

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

MSC-2530818 structure

CAS No.: 1883423-59-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
500 mg	USD 498.00	BP-01942-500mg	In stock	Get quote
1 g	USD 898.00	BP-01942-1g	In stock	Get quote
2 g	Inquire	BP-01942-2g	In stock	Inquire
5 g	Inquire	BP-01942-5g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

MSC2530818 is a potent, selective and orally available CDK8 inhibitor with an IC50 of 2.6 nM for CDK8.

Biological activity

In Vitro MSC2530818 binds to CDK8 and CDK19 with similar affinity (4 nM). Potent inhibition of phospho-STAT1SER727, an established biomarker of CDK8 activity, in SW620 human colorectal carcinoma cells is also observed (pSTAT1SER727 IC50=8±2 nM). MSC2530818 demonstrates potent inhibition of WNT-dependent transcription in human cancer cell lines that have constitutively activated WNT signaling. For example, MSC2530818 inhibits the reporter-based luciferase readout in several cell lines bearing activating WNT-pathway mutations; LS174T (β-catenin mutant, IC50=32±7 nM), COLO205 (APC mutant, IC50=9±1 nM) and demonstrates inhibition of WNT3a ligand-dependent reporter readout in PA-1 cells (IC50=52±30 nM). MSC2530818 demonstrates minimal activity in the CEREP panel, and demonstrates minimal hERG inhibition. Furthermore, MSC2530818 is a soluble CDK8 inhibitor with high permeability and low efflux ratio in Caco-2 cells and does not inhibit any cytochrome P450 subtypes. In Vivo Tumor-bearing mice treated with MSC2530818 shows reduction in tumor growth with T/C ratios (based on final tumor weights) of 49% and 57%, respectively. MSC2530818 is generally well tolerated, with no effects on mouse body weight in the qd administration schedule and manageable body weight loss. The human clearance and volume of distribution at steady-state are estimated to be low (0.14 L/h/kg) and small (0.48 L/kg), respectively, resulting in a short predicted terminal half-life (2.4 h). Physiologically based pharmacokinetics simulations suggested that human oral bioavailability may be ≥75% up to dose level of 500 mg daily.

Identifiers

SMILES: CC1=C2C=C(C=NC2=NN1)C(=O)N1CCC[C@H]1C1=CC=C(Cl)C=C1
InChIKey: ODRITQGYYWHQGM-INIZCTEOSA-N

Specifications

MW (average): 340.8070
Formula: C₁₈H₁₇ClN₄O
CAS No.: 1883423-59-3
Physical state: Solid
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Czodrowski P, et al. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. J Med Chem. 2016 Oct 27;59(20):9337-9349.

Same target

Search CDK

Same research area

Search Cancer